Formulations of organic compounds
US9474534B2 · kind B2 · utility
0Cited by
0References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 4, 2014 |
| Grant date | Oct 25, 2016 |
| Priority date | — |
| Expiry date | Mar 4, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61B2017/12086
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to solid pharmaceutical compositions comprising the phosphatidylinositol 3-kinase inhibitor compound 4-(trifluoromethyl)-5-(2,6-dimorpholinopyrimidin-4-yl)pyridin-2-amine or a pharmaceutically acceptable salt thereof, sodium stearyl fumarate, and optionally at least one additional pharmaceutically acceptable carrier. The present invention also relates to the processes for their preparation and to their use as medicaments for the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.